Secondly, although bioinformatics analyses provide valuable insights, experimental evidence is necessary to achieve a comprehensive understanding of molecular mechanisms, the anti-EGFR inference is pharmacogenomic and associative (DepMap) and requires perturbational validation in EGFR-dependent CRC models (NRG1 gain/loss ± HER3/pan-ERBB inhibition). The gene discussed is ERBB3; the disease is colorectal carcinoma.